Fiera Capital Corp Trims Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Fiera Capital Corp trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 0.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 139,923 shares of the medical research company’s stock after selling 316 shares during the period. Fiera Capital Corp’s holdings in Thermo Fisher Scientific were worth $86,552,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. Burt Wealth Advisors bought a new position in Thermo Fisher Scientific in the 3rd quarter worth approximately $205,000. Capital Performance Advisors LLP purchased a new stake in Thermo Fisher Scientific in the 3rd quarter worth $129,000. AIA Group Ltd boosted its holdings in shares of Thermo Fisher Scientific by 1.8% during the 3rd quarter. AIA Group Ltd now owns 17,676 shares of the medical research company’s stock valued at $10,934,000 after purchasing an additional 309 shares during the last quarter. Verity Asset Management Inc. bought a new stake in shares of Thermo Fisher Scientific in the third quarter worth about $283,000. Finally, Portside Wealth Group LLC lifted its position in shares of Thermo Fisher Scientific by 2.7% in the third quarter. Portside Wealth Group LLC now owns 11,495 shares of the medical research company’s stock worth $7,110,000 after buying an additional 303 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on TMO shares. Sanford C. Bernstein reduced their price objective on Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating on the stock in a research note on Thursday, October 24th. Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Redburn Atlantic initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a “buy” rating and a $680.00 price objective for the company. Stifel Nicolaus decreased their target price on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Finally, Royal Bank of Canada reduced their price objective on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $649.33.

Check Out Our Latest Analysis on Thermo Fisher Scientific

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the transaction, the senior vice president now owns 12,736 shares in the company, valued at approximately $7,134,197.76. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the transaction, the chief executive officer now directly owns 121,192 shares in the company, valued at $67,175,513.68. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the sale, the senior vice president now directly owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,150 shares of company stock worth $10,094,925. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Down 0.3 %

Thermo Fisher Scientific stock traded down $1.89 during trading hours on Friday, reaching $554.00. The stock had a trading volume of 412,588 shares, compared to its average volume of 1,455,518. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The company has a market cap of $211.91 billion, a price-to-earnings ratio of 34.77, a PEG ratio of 3.70 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 52 week low of $437.26 and a 52 week high of $627.88. The business’s 50 day moving average price is $596.33 and its 200-day moving average price is $583.80.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last released its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm’s revenue was up .2% on a year-over-year basis. During the same period in the prior year, the firm earned $5.69 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Articles

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOFree Report).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.